Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 19/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15434003 | 0.86 | FGFR4 (0.65) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL23314963 | 0.83 | FGFR4 (0.52) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL18134023 | 0.73 | FGFR4 (0.51) | FGFR4FGFR1FGFR2FGFR3CYP3A4 | |
| SCHEMBL15413092 | 0.72 | FGFR4 (0.45) | FGFR4FGFR2FGFR3 | |
| SCHEMBL18134024 | 0.70 | FGFR1 (0.39) | FGFR4FGFR1 | |
| SCHEMBL15413315 | 0.70 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL15434004 | 0.66 | FGFR4 (0.62) | FGFR4 | |
| SCHEMBL20094066 | 0.65 | FGFR4 (0.49) | FGFR4FGFR1FGFR2FGFR3CYP1A2 | |
| SCHEMBL21386642 | 0.65 | FGFR4 (0.68) | FGFR4FGFR1FGFR2FGFR3CYP3A4 | |
| SCHEMBL15413472 | 0.62 | FGFR4 (0.70) | FGFR4FGFR1FGFR2FGFR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872491-B1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORP (US) | 2021-05-05 | — | — | EP | disclosed |